Tetraphase Pharmaceuticals, Inc. (TTPH) Reaches $2.80 After 9.00% Down Move; York Water Co (YORW) Sentiment Is 0.91

March 28, 2018 - By Marguerite Chambers

The York Water Company impounds, purifies, and distributes drinking water. The company has market cap of $400.60 million. It owns and operates three wastewater collection systems and two wastewater treatment systems; and has two reservoirs comprising Lake Williams and Lake Redman, which together hold up to approximately 2.2 billion gallons of water. It has a 30.79 P/E ratio. The firm also has a 15-mile pipeline from the Susquehanna River to Lake Redman; and owns seven wells that supply approximately 366,000 gallons of water per day to its clients in Carroll Valley Borough and Cumberland Township, Adams County.

The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) is a huge mover today! The stock decreased 1.75% or $0.05 during the last trading session, reaching $2.8. About 840,047 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 65.91% since March 28, 2017 and is downtrending. It has underperformed by 77.46% the S&P500.The move comes after 7 months negative chart setup for the $144.56M company. It was reported on Mar, 28 by Barchart.com. We have $2.55 PT which if reached, will make NASDAQ:TTPH worth $13.01 million less.

Analysts await Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on May, 3. They expect $-0.47 earnings per share, up 40.51% or $0.32 from last year’s $-0.79 per share. After $-0.46 actual earnings per share reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 2.17% negative EPS growth.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $144.56 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Since January 9, 2018, it had 0 insider buys, and 2 selling transactions for $98,932 activity. On Tuesday, January 9 the insider Dumas Jacques sold $44,507.

Among 16 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 7 have Buy rating, 0 Sell and 9 Hold. Therefore 44% are positive. Tetraphase Pharmaceuticals had 34 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Wednesday, February 14 by SunTrust. On Thursday, October 5 the stock rating was maintained by BMO Capital Markets with “Outperform”. SunTrust upgraded the shares of TTPH in report on Thursday, November 19 to “Buy” rating. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Outperform” rating by BMO Capital Markets on Wednesday, July 26. Needham maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Thursday, August 6 with “Buy” rating. The stock has “Buy” rating by FBR Capital on Wednesday, March 7. The firm has “Market Perform” rating given on Wednesday, February 14 by BMO Capital Markets. FBR Capital initiated the stock with “Buy” rating in Monday, February 12 report. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Market Perform” rating by JMP Securities on Wednesday, September 9. The firm has “Buy” rating by FBR Capital given on Wednesday, February 21.

Investors sentiment decreased to 1.19 in 2017 Q4. Its down 1.02, from 2.21 in 2017Q3. It turned negative, as 11 investors sold Tetraphase Pharmaceuticals, Inc. shares while 25 reduced holdings. 16 funds opened positions while 27 raised stakes. 29.51 million shares or 0.43% more from 29.38 million shares in 2017Q3 were reported. Dow Chem De stated it has 0.1% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Macquarie Gp Limited stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Northern Trust invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Weiss Asset Mgmt Lp has 10,313 shares. Schwab Charles Inv Management invested 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Neuberger Berman Group Inc Ltd Limited Liability Company, New York-based fund reported 22,450 shares. Bnp Paribas Arbitrage Sa holds 0% or 10,989 shares in its portfolio. Susquehanna Gru Llp holds 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 18,626 shares. Panagora Asset Mgmt holds 189,855 shares. Tiaa Cref Invest Mgmt Limited Liability Co accumulated 117,653 shares or 0% of the stock. Geode Cap Management Llc holds 0% or 427,767 shares. Moreover, Jacobs Levy Equity Management Inc has 0.02% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Goldman Sachs Incorporated stated it has 72,524 shares. 33,378 are owned by Paloma Prns. Ellington Mgmt Grp Llc holds 0.03% or 27,000 shares in its portfolio.

Since January 1, 0001, it had 24 insider purchases, and 0 insider sales for $33,921 activity.

Clear Harbor Asset Management Llc holds 0.21% of its portfolio in The York Water Company for 33,275 shares. North Star Investment Management Corp. owns 37,900 shares or 0.16% of their US portfolio. Moreover, Teton Advisors Inc. has 0.14% invested in the company for 44,037 shares. The Pennsylvania-based Philadelphia Trust Co has invested 0.12% in the stock. Manchester Capital Management Llc, a Vermont-based fund reported 22,554 shares.

The stock increased 0.97% or $0.3 during the last trading session, reaching $31.1. About 10,795 shares traded. The York Water Company (YORW) has declined 10.98% since March 28, 2017 and is downtrending. It has underperformed by 22.53% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>